GLENMARK TO LAUNCH DIABETES DRUG TRIAL IN UK

Glenmark will begin the first phase of human trials on its prospective diabetes drug molecule GRC 8200 in the UK.

Phase I of the study is expected to be completed in February 2006. Glenmark has also put a clinical development plan in place for GRC 8200 to reduce the gap with other competing molecules, also in early clinical trials.

The trials will be conducted by Parexel UK, a clinical research organization, and it will be conducted using single and multiple oral doses on healthy volunteers. The objective of this study is to assess the safety and bio-availability of GRC 8200 in humans.